Get started
Author

Paulo Miranda

Observed names: Miranda, Paulo A. P., P. A. P DE MIRANDA, P. A. PALHARES DE MIRANDA, P. Miranda, P.A. Miranda, Paulo A. Miranda, Paulo A. P. Miranda, Paulo A.P. Miranda, Paulo Andre Miranda, Paulo Andre Palhares de Miranda, Paulo André Palhares de Miranda
ORCID: 0000-0001-6853-7531
Observed ORCID: 0000-0001-6853-7531
OpenAlex ID: A5083681267
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
2023 · John F. Seymour, John C. Byrd, et al. · Blood · 143
PDF
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN
2025 · Jeff P. Sharman, Miklos Egyed, et al. · Blood · 50
PDF
A cost evaluation of treatment alternatives for mild‐to‐moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil
2007 · M. C OZELO, P. R VILLAÇA, et al. · Haemophilia · 34
PDF
Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options
2020 · Maria Koufopoulou, Paulo A.P. Miranda, et al. · Cancer Treatment Reviews · 32
Acute Coronary Syndrome Treatment Costs from the Perspective of the Supplementary Health System
2015 · Vanessa Teich, Tony Piha, et al. · Arquivos Brasileiros de Cardiologia · 26
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials
2024 · Matthew S. Davids, Jeff P. Sharman, et al. · Blood Advances · 19
PDF
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma
2022 · Guru P. Sonpavde, Cora N. Sternberg, et al. · European Journal of Cancer · 12
PDF
Analysis of ventricular arrhythmias and sudden death from prospective, randomized clinical trials of acalabrutinib
2024 · Jeff P. Sharman, Paolo Ghia, et al. · British Journal of Haematology · 6
EGFR mutation screening in non-small cell lung cancer: Results from an access program in Brazil.
2014 · Luciola De Barros Pontes, Carlos E Bacchi, et al. · Journal of Clinical Oncology · 5
Preferences for First-Line Chronic Lymphocytic Leukemia Treatments: Results From a Multinational Study on the Perspectives of Patients and Physicians
2025 · Bersabeh Sile, Dipen Patel, et al. · Patient Preference and Adherence · 4
PDF
International survey of attitudes towards secondary prophylaxis with recombinant factor VIIa in haemophilia A patients with inhibitors
2008 · P. M. MANNUCCI, P. A. PALHARES DE MIRANDA · Haemophilia · 4
Cumulative review of hypertension in patients with chronic lymphocytic leukemia treated with acalabrutinib
2024 · Alessandra Ferrajoli, George Follows, et al. · Haematologica · 3
PDF
Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia
2023 · Jeff P. Sharman, Paulo Miranda, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 3
PDF
Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)
2021 · John F. Seymour, John C. Byrd, et al. · Blood · 3
Cardiovascular safety outcomes of chronic lymphocytic leukemia treatments: A systematic and targeted literature review
2025 · Yen-Chou Chen, Paulo Miranda, et al. · Critical Reviews in Oncology/Hematology · 2
Cardiac Events in Three Phase 3 Randomized Trials Including Acalabrutinib in Chronic Lymphocytic Leukemia
2025 · Rupal O’Quinn, Anthony J. Corry, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Interim safety results for fixed-dose durvalumab (D) monotherapy (module A).
2020 · Guru Sonpavde, Cora N. Sternberg, et al. · Journal of Clinical Oncology · 2
A phase 3b safety study of fixed-dose durvalumab + tremelimumab or durvalumab monotherapy in advanced solid malignancies (STRONG): Urothelial and non-urothelial urinary tract carcinoma module A.
2018 · Guru Sonpavde, Solange Peters, et al. · Journal of Clinical Oncology · 2
Matching-adjusted indirect comparison of acalabrutinib versus ibrutinib in relapsed/refractory mantle cell lymphoma
2024 · Ling Cai, Jack Roos, et al. · Journal of Medical Economics · 1
P667: Long-term Efficacy of Acalabrutinib-based Regimens in Patients With Chronic Lymphocytic Leukemia and Higher-risk Genomic Features: Pooled Analysis of Clinical Trial Data
2022 · M. Davids, J. Sharman, et al. · HemaSphere · 1
Efficacy, Safety and Economic Evaluation of Recombinant Activated Factor VII (rFVIIa) in the Management of Mild and Moderate Bleedings in Haemophilia Patients with Inhibitors in Brazil.
2006 · Margareth C. Ozelo, Paula R. Villaça, et al. · Blood · 1
An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Final analysis for fixed-dose durvalumab monotherapy (module A).
2021 · Guru Sonpavde, Aurelien Marabelle, et al. · Journal of Clinical Oncology
PMS39 Cost-Effectiveness Analysis of Certolizumab Pegol in Patients With Rheumathoid Arthritis from a Brazilian Private Perspective
2012 · T. Piha, E.D.S. Meirelles, et al. · Value in Health
To the Editor
2008 · Paulo André Palhares de Miranda, Pamela D. Reiter · Clinical and Applied Thrombosis/Hemostasis
Works count: 25
Citation count: 354
H-index: 7
I10-index: 7
Year
Topic
Type